Revolution Medicines Inc (RVMD) Noticias

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form 8-K - Current report

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

 Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability...

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor...

Form 4 - Statement of changes in beneficial ownership of securities

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 144 - Report of proposed sale of securities

Form S-4/A - Registration of securities, business combinations: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities